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ABSTRACT 
Osteoporosis is characterized by low bone mineral density (BMD) and loss of the structural and biomechanical properties that are required to 
maintain bone homeostasis. Physicians are knowledgeable about the association of osteoporosis with aging, postmenopausal status, and 
secondary causes, including chronic illnesses or lifestyle issues that promote osteoporosis. Building strong and healthy bones requires an 
adequate dietary intake of calcium beginning in childhood and adolescence for both sexes. Most importantly, however, a high dietary calcium 
intake or taking calcium supplements alone is not sufficient in treating osteoporosis and should not be viewed as an alternative to or 
substituted for more potent prescription medications for osteoporosis.  
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1. INTRODUCTION: 
Osteoporosis afflicts 10 million Americans, and another 30 
million Americans have low bone mass that puts them at risk 
for development of osteoporosis1. The overall risk for a 50-
year-old Caucasian or Asian woman to sustain an 
osteoporotic fracture during her lifetime is 50%. While men, 
African Americans, and Hispanics have lower risks, the 
health impact is still substantial. One-third of all hip 
fractures occur in men, and with our aging populace hip 
fracture incidence in men will eventually approach that of 
women1. A femoral neck or trochanteric fracture is 
associated with mortality of approximately 20%1 
2. DIAGNOSIS: 
Osteoporosis diagnostics can be complicated. The World 
Health Organization (WHO) defined osteoporosis as a 
systemic skeletal disease characterized by low bone mass 
with microarchitectural deterioration of bone tissue, thus 
increasing bone fragility and susceptibility to fracture1. For 
screening purposes, osteoporosis was defined by the WHO 
as a bone mineral density (BMD) at any site equal to or 
greater that 2.5 standard deviations below the fracture 
resistant mean peak bone mass of young adulthood. 
3. SIGN AND SYMPTOMS: 
Bone loss that leads to osteoporosis develops slowly. There 
are often no symptoms or outward signs, and a person may 
not know they have it until they experience a fracture3 after 
a minor incident, such as a fall, or even a cough or sneeze. 
 Commonly affected areas are the hip, a wrist, or spinal 
vertebrae4. 
 Breaks in the spine can lead to changes in posture, a 
stoop, and curvature of the spine. 
4. CAUSES OF BONE FRAGILE: 
Your skeleton is an active vital organ. It keeps you healthy 
through a constant process of repair, renewal, and mineral 
release. This process is called remodeling. The bone 
remodeling cycle consists of two distinct stages:  
(1) bone resorption5 (breakdown and removal) and 
 (2) bone formation (generation of new bone).  
During resorption, cells on the bone’s surface called 
osteoclasts dissolve bone tissue, releasing it into the 
bloodstream and leaving behind tiny pits, or cavities. Then, 
during formation, cells called osteoblasts fill these cavities 
with new bone tissue. In normal bone, resorption and 
formation are in lock step, with one matching the other.6 
5. MEDICATION TO PREVENT FRAGALITY 
FRACTURES: 
Here are many medications available to treat osteoporosis 
and reduce the risk of fracture. They fall into two basic 
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categories: antiresorptives and anabolics. Antiresorptive 
drugs include bisphosphonates (alendronate, ibandronate, 
risedronate, zoledronic acid), denosumab, calcitonin, 
estrogen/estrogen-progestin, an estrogen 
agonist/antagonist (raloxifene), and a tissue specific 
estrogen complex (estrogen/bazedoxifene).7-15 
6. MEDICATION FOR TREATMENT OF 
OSTEOPOROSIS: 
Bisphosphonates are the most common medications 
prescribed for osteoporosis treatment. These include: 
 Alendronate (Fosamax)9 
 Risedronate (Actonel)10 
 Ibandronate (Boniva)12 
 Zoledronic acid (Reclast)14 
Hormones, such as estrogen, can play a role in osteoporosis 
prevention and treatment. However, there has been some 
concern about potential side effects tied to the use of 
hormone therapy.16 Current recommendations say to use the 
lowest dose of hormones for the shortest period of time. 
7. DRUG THERAPY: 
Drugs that can help prevent and treat osteoporosis include: 
 Bisphosphonates: These are antiresorptive drugs that 
slow bone loss and reduce fracture risk.9 
 Estrogen agonists or antagonists, also known as 
selective estrogen-receptor modulators, SERMS), for 
example, raloxifene (Evista): These can reduce the risk 
of spine fractures in women after menopause.17 
 Calcitonin (Calcimar, Miacalcin): This helps prevent 
spinal fracture in postmenopausal women, and it can 
help manage pain if a fracture occurs.11 
 Parathyroid hormone, for example, teriparatide 
(Forteo): This is approved for people with a high risk 
of fracture, as it stimulates bone formation. 
 Monoclonal antibodies18 (denosumab, romosozumab): 
These are immune therapies given to some 
postmenopausal women with osteoporosis. 
Romosuzumab carries a black box warning due to 
possible adverse effects. 
7.1 Specific Drug Treatments Include: 
 Bisphosphonates9 
 Denosumab 
 Parathyroid Hormone 
 Hormone Therapy 
 SERMs19 (Selective Estrogen Receptor Modulators) 
8. CONSEQUENCES OF OSTEOPOROSIS: 
Osteoporotic bone fractures are responsible for considerable 
pain, decreased quality of life, lost workdays, and disability. 
Up to 30% of patients suffering a hip fracture will require 
long-term nursing-home care. Elderly patients can develop 
pneumonia and blood clots in the leg veins that can travel to 
the lungs (pulmonary embolism) due to prolonged bed rest 
after the hip fracture. Osteoporosis has even been linked 
with an increased risk of death.20 Some 20% of women with 
a hip fracture will die in the subsequent year as an indirect 
result of the fracture. In addition, once a person has 
experienced a spine fracture due to osteoporosis, he or she is 
at very high risk of suffering another such fracture in the 
near future (next few years).21 About 20% of 
postmenopausal women who experience a vertebral fracture 
will suffer a new vertebral fracture of bone in the following 
year. 
9. CONCLUSION:  
The goal of treatment of osteoporosis is the prevention of 
bone fractures by reducing bone loss or, preferably, by 
increasing bone density and strength. Although early 
detection and timely treatment of osteoporosis can 
substantially decrease the risk of future fractures, none of 
the available treatments for osteoporosis are complete 
cures. In other words, it is difficult to completely rebuild 
bone that has been weakened by osteoporosis. Therefore, 
prevention of osteoporosis is as important as treatment. 
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